Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT01412424 : Efficacy and Safety of Octreolin for Acromegaly
PhasePhase 3
AgesMin: 18 Years Max: 75 Years
Eligibility
Inclusion Criteria:

- Adult subjects, aged 18 to 75 years old, inclusive

- Subjects with acromegaly defined as documented evidence of GH-secreting pituitary
tumor that is abnormally responsive to glucose who are currently receiving a
somatostatin analog

- Subjects able and willing to comply with the requirements of the protocol

- Subjects able to swallow capsules

- Subjects able to understand and sign written informed consent to participate in the
study

Exclusion Criteria:

- Symptomatic cholelithiasis

- Received pituitary radiotherapy within ten years prior to screening

- Undergone pituitary surgery within the prior 6 months

- Clinically significant GI, renal or hepatic disease

- Known allergy or hypersensitivity to any of the test compounds or materials

- Life expectancy of less than 2 years

- Uncontrolled diabetes

- Defects in visual fields due to optic chiasmal compression

- Female patients who are pregnant or lactating

- Female patients who are of childbearing potential

- History of immunocompromise, including a positive HIV test result (ELISA and Western
blot)

- History of alcohol or drug abuse

- Intake of an investigational drug within 30 days before patient inclusion in this
study
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT01412424      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2018 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740